1122TiP A phase II trial to evaluate the safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs) | Publicación